Synapse - Ronglai Shen

Molecular characteristics predict clinical outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene

Journal Article

Rizvi, N. A.; Rusch, V.; Pao, W.; Chaft, J. E.; Ladanyi, M.; Miller, V. A.; Krug, L. M.; Azzoli, C. G.; Bains, M.; Downey, R.; more...
Clinical Cancer Research (2011)

Fulltext@MSK | Save

Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations

Journal Article

Janjigian, Y. Y.; Park, B. J.; Zakowski, M. F.; Ladanyi, M.; Pao, W.; D'Angelo, S. P.; Kris, M. G.; Shen, R.; Zheng, J.; Azzoli, C. G.
Journal of Thoracic Oncology (2011)

Fulltext@MSK | Save

Breast cancer methylomes establish an epigenomic foundation for metastasis

Journal Article

Fang, F.; Turcan, S.; Rimner, A.; Kaufman, A.; Giri, D.; Morris, L. G. T.; Shen, R.; Seshan, V.; Mo, Q.; Heguy, A.; more...
Science Translational Medicine (2011)

Fulltext@MSK | Save

A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer

Journal Article

Fury, M. G.; Haque, S.; Stambuk, H.; Shen, R.; Carlson, D.; Pfister, D.
Cancer (2011)

Fulltext@MSK | Save

Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)

Journal Article

Fury, M. G.; Baxi, S.; Shen, R.; Kelly, K. W.; Lipson, B. L.; Carlson, D.; Stambuk, H.; Haque, S.; Pfister, D. G.
Anticancer Research (2011)

Fulltext@MSK | Save